DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer

Growing body of recent data support VAL-083 s potential as a treatment for drug-resistant non-small cell lung cancer VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 8, 2015, OTCQX, DMPI, /PRNewswire/  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ( DelMar and the Company ), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented an overview of its planned clinical trial protocol for Company s lead product candidate VAL-083(dianhydrogalactitol) in the treatment of non-small cell lung cancer (NSCLC). The Company presented the VAL-083 NSCLC clinical development plan in a poster entitled, Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer at the 16th World Conference on Lung Cancer in Denver, Colorado. VAL-083 is a first-in-class bi-functional alkylating agent meditating inter-strand DNA crosslinks at N7 of guanine that has been approved by the Chines


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: